In the new study, two medicines against Alzheimer’s disease prove effective
A new study has shown that two drugs – lekainmabs and donanmabs – can help patients to remain independent for about 10–13 months in the early stages of Alzheimer’s disease.
In short
- Lecanemab and Donanemab can help patients live independently
- Alzheimer’s disease is a degenerative brain disorder affecting memory
- Two drugs can help patients stay independent for 10-13 months
Two drugs have proved to be effective treatment for Alzheimer’s disease, which are the fastest growing neurological disorders in the world. While Alzheimer’s has no cure, most of the treatment completes the symptoms of the disease. However, a new study has shown that two drugs – but can help patients to remain independent for about 10–13 months in the initial stage.
Typically, in Alzheimer’s disease, patients require help because they have their memory, speech, decision making, reading and writing difficulty and even simple daily activities.
Lychenmab and Donanamb have proved to delay the aid for patients, which are in their early stages of brain disorders. According to researchers at the Washington University School of Medicine, a person with very light symptoms can live independently for 29 months, without treatment vs. 39 months with lekenum.
Pire-review Journal Alzheimer’s and Dementia: Published in Translations and Clinical Intervention, the study focused on individuals with early stages of Alzheimer’s disease, who would be eligible for new anti-amyloid treatment.
These treatments help to remove amyloid plaques in the brain, which is a major feature of Alzheimer’s disease.
Lecanemab (approved by US Food and Drugs Administration in July 2023) and Donanmab (FDA-innovated in July 2024) have shown a minor but statistically significant impact in slowing the progression of the disease in clinical trials.
Lecanemab is an antibody intravenous infusion therapy that targets and removes beta-amyloid in the brain. It was approved for early treatment of Alzheimer’s. Although this is not a cure, it has become a traditionally approved treatment that addresses the underlying biology of Alzheimer’s and changes the course of the disease for better response.
While Lencmab is sold in the US, Japanese pharmaceutical giant Christians are trying to launch drugs in India.
Donanmab, another traditionally approved drug that has the same effect as but is a monoclonal antibod that binds the amyloid plaque in the brain. It teaches the body’s immune system to identify the plaque and remove it from the brain. It helps to slow down the progress of Alzheimer’s and is given in intravenous every four weeks.
The US pharmaceutical giant Eli Lily aims to introduce Dononamb in India in 2025.
